Waks Jonathan W, Higgins Angela Y, Mittleman Murray A, Buxton Alfred E
Harvard-Thorndike Electrophysiology Institute, Department of Cardiovascular Diseases, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
J Cardiovasc Electrophysiol. 2015 Mar;26(3):282-90. doi: 10.1111/jce.12589. Epub 2015 Jan 7.
Impaired renal function is associated with increased mortality among patients with implantable cardioverter-defibrillators (ICDs). The relationship between renal function at time of ICD generator replacement and subsequent appropriate ICD therapies is not known.
We identified 441 patients who underwent first ICD generator replacement between 2000 and 2011 and had serum creatinine measured within 30 days of their procedure. Patients were divided into tertiles based on estimated glomerular filtration rate (eGFR). Adjusted Cox proportional hazard and competing risk models were used to assess relationships between eGFR and subsequent mortality and appropriate ICD therapy. Median eGFR was 37.6, 59.3, and 84.8 mL/min/1.73 m(2) for tertiles 1-3, respectively. Five-year Kaplan-Meier survival probability was 34.8%, 61.4%, and 84.5% for tertiles 1-3, respectively (P < 0.001). After multivariable adjustment, compared to tertile 3, worse eGFR tertile was associated with increased mortality (HR 2.84, 95% CI [1.36-5.94] for tertile 2; HR 3.84, 95% CI [1.81-8.12] for tertile 1). At 5 years, 57.0%, 58.1%, and 60.2% of patients remained free of appropriate ICD therapy in tertiles 1-3, respectively (P = 0.82). After adjustment, eGFR tertile was not associated with future appropriate ICD therapy. Results were unchanged in an adjusted competing risk model accounting for death.
At time of first ICD generator replacement, lower eGFR is associated with higher mortality, but not with appropriate ICD therapies. The poorer survival of ICD patients with reduced eGFR does not appear to be influenced by arrhythmia status, and there is no clear proarrhythmic effect of renal dysfunction, even after accounting for the competing risk of death.
肾功能受损与植入式心脏复律除颤器(ICD)患者的死亡率增加相关。ICD发生器更换时的肾功能与随后的适当ICD治疗之间的关系尚不清楚。
我们确定了441例在2000年至2011年间接受首次ICD发生器更换且在手术30天内测量血清肌酐的患者。根据估计的肾小球滤过率(eGFR)将患者分为三分位数。使用调整后的Cox比例风险模型和竞争风险模型来评估eGFR与随后的死亡率和适当ICD治疗之间的关系。三分位数1-3的eGFR中位数分别为37.6、59.3和84.8 mL/min/1.73 m²。三分位数1-3的五年Kaplan-Meier生存概率分别为34.8%、61.4%和84.5%(P<0.001)。多变量调整后,与三分位数3相比。eGFR较差的三分位数与死亡率增加相关(三分位数2的HR为2.84,95%CI[1.36-5.94];三分位数1的HR为3.84,95%CI[1.81-8.12])。5年时,三分位数1-3分别有57.0%、58.1%和60.2%的患者未接受适当的ICD治疗(P=0.82)。调整后,eGFR三分位数与未来适当的ICD治疗无关。在考虑死亡因素的调整竞争风险模型中,结果不变。
在首次ICD发生器更换时,较低的eGFR与较高的死亡率相关,但与适当的ICD治疗无关。eGFR降低的ICD患者较差的生存率似乎不受心律失常状态的影响,即使在考虑了死亡的竞争风险后,肾功能不全也没有明显的促心律失常作用。